{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"To determine the safety and tolerability of pembrolizumab administered after radiation therapy in patients with MPM. The primary endpoint was \"unaccepable\" high grade adverse events (AEs) from baseline to 4-month after the start of radiation therapy.","groups":[{"description":"Patient with lung intact to receive hemithoracic radiation therapy for definitive intent","id":"OG000","title":"Cohort 1"},{"description":"Patients with lung intact to receive non-hemithoracic radiation therapy(palliative radiation therapy)","id":"OG001","title":"Cohort 2"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Baseline to 4-months after the start of radiation therapy","title":"Safety/Toxicity","type":"PRIMARY","unitOfMeasure":"participants"}